Dr Roxie Mooney, DBA
Orlando, Florida
Overview
I help mid-market healthtech and pharmacy companies increase enterprise value before scale or exit. I work with: CEOs preparing for premium acquisition or institutional scale CMOs under board-level scrutiny for ROI and GTM alignment PE operating partners accelerating portfolio value creation Most companies do not lose valuation during diligence. They lose it earlier through: Fragmented positioning Misaligned GTM systems Founder-dependent narratives Weak proof structures Buyers form conviction before the process begins. Legacy DNA is a commercialization and valuation partner built s
About
I help mid-market healthtech and pharmacy companies increase enterprise value before scale or exit. I work with: CEOs preparing for premium acquisition or institutional scale CMOs under board-level scrutiny for ROI and GTM alignment PE operating partners accelerating portfolio value creation Most companies do not lose valuation during diligence. They lose it earlier through: Fragmented positioning Misaligned GTM systems Founder-dependent narratives Weak proof structures Buyers form conviction before the process begins. Legacy DNA is a commercialization and valuation partner built specifically for mid-market healthcare complexity. We build: Buyer-ready narratives that transfer beyond the founder GTM systems aligned across brand, demand, and sales Commercialization dashboards boards can defend Proof structures that reduce diligence friction Our work is grounded in the Commercialization of Innovation framework and 20+ years of healthcare commercialization experience. I’ve helped launch 100+ healthcare innovations and contributed to BioPlus Specialty Pharmacy’s growth from $750M to $2B through two acquisitions. Clarity is a valuation lever. If you are 12–36 months from an exit, preparing for acquisition, or facing sharper board conversations, start with the Exit Readiness Scorecard: https://legacy-dna.com/exit-readiness-scorecard Or Book a strategy call at www.strategicfitcall.com